Assessment of right ventricular dysfunction predictors before the implantation of a left ventricular assist device in end-stage heart failure patients using echocardiographic measures (ARVADE): Combination of left and right ventricular echocardiographic variables  by Aissaoui, Nadia et al.
AC
A
p
v
f
m
a
v
É
a
c
v
d
E
v
d
s
1rchives of Cardiovascular Disease (2015) 108, 300—309
Available  online  at
ScienceDirect
www.sciencedirect.com
LINICAL RESEARCH
ssessment  of  right  ventricular  dysfunction
redictors  before  the  implantation  of  a  left
entricular  assist  device  in  end-stage  heart
ailure  patients  using  echocardiographic
easures  (ARVADE):  Combination  of  left
nd  right  ventricular  echocardiographic
ariables
valuation  de  la  fonction  ventriculaire  droite  avant  implantation  d’une
ssistance  ventriculaire  mono-gauche  chez  les  patients  en  insufﬁsance
ardiaque  terminale  par  échocardiographie  :  combinaison  de  paramètres
entriculaires  gauches  et  droits
Nadia  Aissaouia,b,c,d,∗,  Joe-Elie  Salema,
Lech  Paluszkiewiczb,  Michiel  Morshuisb,
Emmanuel  Guerota,  Gonzalo  Martin  Gorriab,
Jean-Yves  Fagona,d,  Jan  Gummertb,
Benoit  Diebolda,c,d
a Georges-Pompidou  European  Hospital,  Assistance  Publique  des  Hôpitaux  de  Paris  (AP—HP),
Paris, France
b Heart  and  Diabetes  Centre,  NRW,  Bad  Oeynhausen,  Germany
c Faculty  of  Medicine,  University  Paris  Descartes,  Paris,  France
d INSERM  U  678,  University  Paris  VI,  Paris,  France
Received  29  June  2014;  received  in  revised  form  22  September  2014;  accepted  13  January  2015
Available online  8  April  2015Abbreviations: AUC, area under the curve; BiVAD, biventricular assist device; CI, conﬁdence interval; ELAT, tissue Doppler lateral
iastolic velocity; ERV, tissue Doppler RV diastolic velocity; ESEPT, tissue Doppler septal diastolic velocity; Em, pulsed Doppler transmitral
 wave; Et, pulsed Doppler tricuspidal E wave; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LV, left
entricle/ventricular; LVAD, LV assist device; RR, relative risk; RV, right ventricle/ventricular; RVAD, RV assist device; RVEDD, RV end-diastolic
iameter; RVF, RV failure; SLAT, tissue Doppler lateral systolic velocity; SRV, tissue Doppler RV systolic velocity; SSEPT, tissue Doppler septal
ystolic velocity; TAPSE, maximal systolic excursion of the tricuspid annulus; VAD, ventricular assist device.
∗ Corresponding author at: Service de réanimation médicale, hôpital européen Georges-Pompidou, 25, rue Leblanc, 75015 Paris, France.
E-mail address: nadia.aissaoui@egp.aphp.fr (N. Aissaoui).
http://dx.doi.org/10.1016/j.acvd.2015.01.011
875-2136/© 2015 Elsevier Masson SAS. All rights reserved.
RV  dysfunction  predictors  before  LVAD  implantation  301
KEYWORDS
Right  ventricular
failure;
INTERMACS  level;
Assist  device;
Doppler  tissue
velocities;
Echocardiography
Summary
Background.  —  Right  ventricular  failure  (RVF)  is  a  major  cause  of  morbidity  and  mortality  in  left
ventricular  assist  device  (LVAD)  recipients.
Objectives.  —  To  identify  preoperative  echocardiographic  predictors  of  post-LVAD  RVF.
Methods.  —  Data  were  collected  for  42  patients  undergoing  LVAD  implantation  in  Germany.  RVF
was deﬁned  as  the  need  for  placement  of  a  temporary  right  ventricular  assist  device  or  the  use
of inotropic  agents  for  14  days.  Data  for  RVF  patients  were  compared  with  those  for  patients
without RVF.  A  score  (ARVADE)  was  established  with  independent  predictors  of  RVF  by  rounding
the exponentiated  regression  model  coefﬁcients  to  the  nearest  0.5.
Results.  —  RVF  occurred  in  24  of  42  LVAD  patients.  Univariate  analysis  identiﬁed  the  following
measurements  as  RVF  risk  factors:  basal  right  ventricular  end-diastolic  diameter  (RVEDD),  min-
imal inferior  vena  cava  diameter,  pulsed  Doppler  transmitral  E  wave  (Em),  Em/tissue  Doppler
lateral systolic  velocity  (SLAT)  ratio  and  Em/tissue  Doppler  septal  systolic  velocity  (SSEPT)  ratio.
Em/SLAT ≥  18.5  (relative  risk  [RR]  2.78,  95%  conﬁdence  interval  [CI]  1.38—5.60;  P  =  0.001),
RVEDD ≥  50  mm  (RR  1.97,  95%  CI  1.21—3.20;  P  =  0.008)  and  INTERMACS  (Interagency  Registry
for Mechanically  Assisted  Circulatory  Support)  level  1  (RR  1.74,  95%  CI  1.04—2.91;  P  =  0.04)
were independent  predictors  of  RVF.  An  ARVADE  score  >  3  predicted  the  occurrence  of  post-
implantation  RVF  with  a  sensitivity  of  89%  and  a  speciﬁcity  of  74%.
Conclusion.  —  The  ARVADE  score,  combining  one  clinical  variable  and  three  echocardiographic
measurements,  is  potentially  useful  for  selecting  patients  for  the  implantation  of  an  assist
device.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’insufﬁsance  ventriculaire  droite  (IVD)  en  post-implantation  d’une  assistance
mono-gauche  (ACM-MG)  est  une  cause  importante  de  morbi-mortalité.
Objectifs.  — L’objectif  principal  de  notre  étude  était  d’identiﬁer  des  paramètres  échocardio-
graphiques  prédictifs  de  la  survenue  d’une  IVD  après  l’implantation  d’une  ACM-MG  chez  les
patients  en  insufﬁsance  cardiaque  terminale.
Méthodes.  — Les  données  cliniques,  hémodynamiques  et  échocardiographiques  étaient  recueil-
lies prospectivement  chez  42  patients  en  insufﬁsance  cardiaque  terminale  devant  bénéﬁcier
d’une ACM-MG.  Ces  données  étaient  comparées  entre  les  patients  développant  une  IVD  en
post-implantation  et  ceux  ne  la  développant  pas.  L’IVD  en  postopératoire  d’une  ACM-MG  était
déﬁnie par  la  nécessité  d’une  assistance  circulatoire  droite  ou  d’inotropes  au  moins  14  jours
après l’implantation  de  l’ACM-MG.  Un  score  « ARVADE  » était  établi  en  additionnant  des  points
déterminés  en  fonction  de  la  valeur  des  facteurs  prédictifs  d’IVD.
Résultats.  —  Parmi  les  42  patients  inclus,  24  (57  %)  ont  développé  une  IVD  en  post-implantation
de l’ACM-MG.  Les  facteurs  de  risque  en  analyse  univariée  de  développer  une  IVD  après
l’implantation  d’une  ACM-MG  étaient:  le  stade  INTERMACS,  le  diamètre  télédiastolique  basal  du
VD (DTDVD),  le  diamètre  minimal  de  la  veine  cave  inférieur,  l’onde  E  mitrale  (Em)  et  les  rapports
Em/onde S  latérale  et  Em/onde  S  septale.  En  analyse  multivariée,  les  facteurs  prédictifs  d’une
IVD étaient  un  rapport  Em/SLAT  ≥  18,5  (RR  2,78,  IC  1,38—5,60  ;  p  =  0,001),  un  DTDVD  ≥  50  mm
(RR 1,97,  IC  1,21—3,20  ;  p  =  0,008)  et  un  stade  1  INTERMACS  (RR  1,74,  CI  1,04—2,91;  p  =  0,04).
Un score  ARVADE  >  3  permettait  de  prédire  une  IVD  en  post-implantation  avec  une  sensibilité  de
89 %  et  une  spéciﬁcité  de  74  %.
Conclusion.  —  Le  score  ARVADE  associant  des  paramètres  échographiques  reﬂétant  le  fonction-
nement de  VG  et  du  VD  et  un  paramètre  clinique  pronostique  pourrait  permettre  une  meilleure
sélection  des  candidats  à  une  ACM-MG.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
OBackgroundVentricular  assist  devices  (VADs)  are  a  life-saving  thera-
peutic  option  for  patients  with  end-stage  heart  failure.
l
t
ine-year  survival  after  implantation  of  a left  ventricu-
ar  assist  device  (LVAD)  in  selected  patients  is  similar
o  that  after  heart  transplant  [1],10  although  survival
s  limited  by  early  morbidity  and  mortality  caused  by
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ight  ventricular  failure  (RVF)  [2,3].  Indeed,  RVF  failure
as  an  incidence  of  up  to  50%  after  LVAD  implanta-
ion  and  results  in  perioperative  mortality  and  morbidity
ates  of  19  to  43%,  including  end-organ  dysfunction  asso-
iated  with  prolonged  intensive  care  and  hospitalization
2,4,5].
Numerous  factors  contribute  to  RVF  after  LVAD  implan-
ation,  rendering  the  prediction  and  management  of
ostoperative  right  ventricular  (RV)  dysfunction  complex
2,4—6].  The  identiﬁcation  of  predictors  of  RVF  in  preoper-
tive  VAD  patients  would  improve  the  selection  of  patients
ost  likely  to  beneﬁt  from  LVAD.
Various  clinical  factors  (being  female,  non-ischaemic
etiology  of  LV  dysfunction)  and  haemodynamic  factors  (high
entral  venous  pressure,  low  mean  pulmonary  artery  pres-
ure  and  low  RV  stroke  work  index)  have  been  identiﬁed
s  independent  predictors  of  RVF  after  LVAD  implantation
1—7].  However,  no  single  factor  reliably  predicts  RVF  in
hese  conditions.
Risk  scores,  based  on  the  independent  predictors  of
VF,  combining  clinical,  haemodynamic  and  laboratory  mea-
urements,  may  be  useful  for  predicting  RVF,  but  no
core  of  this  type  has  been  tested  prospectively  [4,5].
he  Michigan  RV  score  can  be  useful  in  very  severely
ffected  patients,  with  high  scores  reﬂecting  multiple  organ
ailure  (requirement  for  vasopressors,  renal  and  hepatic
ongestion),  but  its  utility  is  limited  in  less  severe  cases
4,7].
RV  echocardiographic  variables,  including  two-
imensional  global  strain  imaging,  have  been  reported  to
rovide  valuable  information  about  RV  risk,  but  conﬂicting
esults  have  been  obtained  [8—11].  The  complex  geometry
f  the  right  ventricle  (RV)  also  makes  it  difﬁcult  to  assess
V  function.
Left  ventricular  (LV)  evaluation  may  be  useful  for  RVF
rediction  [12].  Severe  and  advanced  LV  dysfunction  has
onsequences  for  RV  function,  and  impaired  LV  contractil-
ty  has  a  negative  effect  on  RV  function.  Left-sided  heart
isease  causes  pulmonary  venous  congestion  and  pulmonary
enous  hypertension.  Chronic  sustained  high  blood  pressure
n  pulmonary  capillaries  leads  to  a  cascade  of  pathological
etrograde  anatomical  and  functional  effects,  resulting  in
V  overload  and  failure  [13].  It  may,  therefore,  be  possible
o  predict  the  likelihood  of  RVF  after  LVAD  implantation,  at
east  partially,  from  assessments  of  LV  function.  In  partic-
lar,  tissue  Doppler  systolic  myocardial  velocity  and  the  E
ave,  an  indicator  of  LV  relaxation  disorder  and  overload,
ay  be  useful.
The  main  aim  of  this  study  was  to  identify  preopera-
ive  echocardiographic  predictors  of  post-LVAD  RVF  and  to
valuate  a  risk  score  for  postoperative  RVF.
ethods
tudy
his  study  complied  with  the  Helsinki  Declaration  and
as  approved  by  the  ethics  committee  of  our  institution.
nformed  consent  was  not  sought  from  the  patients,  as  this
as  an  observational  study  and  did  not  involve  any  changes
o  diagnostic  tests  or  therapeutic  interventions.
d
e
g
(N.  Aissaoui  et  al.
atient selection
ata  were  collected  prospectively  for  all  patients  who
nderwent  elective  LVAD  or  biventricular  VAD  (BiVAD)
mplantation  and  preoperative  echocardiography  between
ovember  2010  and  August  2011,  at  the  Clinic  for  Thoracic
nd  Cardiovascular  Surgery  in  Bad  Oeynhausen,  Germany.
he  devices  implanted  were  the  HeartMate  II  (Thoratec,
leasanton,  CA,  USA),  the  HeartWare  HVAD  (HeartWare,
akville,  CA,  USA)  and  the  Thoratec  Paracorporeal  BiVAD
Thoratec,  Pleasanton,  CA,  USA).  Patients  receiving  a  total
rtiﬁcial  heart  were  excluded  from  the  analysis  because,  at
ur  institution,  the  choice  to  implant  a  total  artiﬁcial  heart
as  often  based  on  the  presence  of  mechanical  prostheses,
ctive  endocarditis,  severe  pulmonary  insufﬁciency,  exten-
ive  LV  apical  thrombus  or  hypertrophic  cardiomyopathy.
atients  were  also  excluded  if  image  quality  was  deemed
nsufﬁcient  for  the  analysis  of  RV  function.
linical data
aseline  clinical,  demographic,  haemodynamic  and  labo-
atory  data  were  recorded  prospectively  in  the  electronic
ecord.  An  Interagency  Registry  for  Mechanically  Assisted
irculatory  Support  (INTERMACS)  proﬁle  [14]  and  Michi-
an  RV  risk  score  [4]  were  calculated  for  each  patient.
he  Michigan  score  assigns  points  based  on  four  variables,
ith  vasopressor  use  adding  4  points,  creatinine  >  2.3  mg/dL
dding  3  points,  bilirubin  >  2  mg/dL  adding  2.5  points
nd  aspartate  aminotransferase  >  80  IU/dL  adding  2  points.
igher  scores  (especially  if  ≥  5.5)  are  associated  with  a
reater  risk  of  RVF.
Patients  with  a  glomerular  ﬁltration  rate  <  60  mL/min/
.73  m2 for  3  months  were  classiﬁed  as  having  chronic  renal
nsufﬁciency.
Deaths  during  hospitalization  and  the  causes  of  death
ere  recorded.  Univariate  risk  factors  for  death  were  ana-
ysed.
chocardiographic assessment
reoperative  transthoracic  echocardiography  results  were
eviewed  and  analysed  by  a  reader  blinded  to  clinical  out-
ome.  Standard  echocardiographic  measurements  of  the
V  were  made  in  accordance  with  current  guidelines  [15],
ncluding  basal  RV  end-diastolic  diameter  (RVEDD),  end-
ystolic  and  end-diastolic  RV  areas,  fractional  area  change,
aximal  systolic  excursion  of  the  tricuspid  annulus  (TAPSE),
issue  Doppler  systolic  and  diastolic  velocities  of  the  RV  lat-
ral  wall  (SRV and  ERV),  pulsed  Doppler  tricuspid  E  wave  (Et),
ystolic  pulmonary  arterial  pressure  and  maximal  and  mini-
al  diameters  of  the  inferior  vena  cava.  Longitudinal  strain
f  the  RV  free  wall  was  measured  on  the  stored  DICOM  loops
ith  standard  commercially  available  software  (QLAB  CMQ,
hilips,  Amsterdam,  Netherlands).  Images  were  searched
or  evidence  of  severe  mitral,  aortic,  tricuspid  and  pul-
onary  regurgitation.  The  systolic  and  diastolic  functions  of
he  left  ventricle  (LV)  were  also  assessed:  LV  end-diastolic
iameter  and  volume,  LV  end-systolic  diameter  and  volume,
jection  fraction  (Biplan  Simpson),  aortic  time-velocity  inte-
ration,  tissue  Doppler  imaging,  systolic  and  diastolic  lateral
SLAT and  ELAT) and  septal  (SSEPT and  ESEPT)  velocities,  pulsed
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ERV  dysfunction  predictors  before  LVAD  implantation  
Doppler  transmitral  E  wave  (Em)  and  mitral  deceleration
time.
Several  markers  were  calculated:  cardiac  index,  right-
to-left  ventricular  end-diastolic  diameter,  Et/ERV ratio,
Em/ESEPT ratio,  Em/ELAT ratio,  Em/SSEPT ratio  and  Em/SLAT
ratio.
Data collection
The  data  were  collected  in  the  24  hours  before  LVAD  implan-
tation.  The  median  period  between  admission  and  VAD
implantation  was  5.0  days  (interquartile  range,  2.0—7.0).
Outcomes
Patients  were  divided  into  three  groups:  LVAD  patients  with-
out  RVF,  LVAD  patients  with  RVF  and  patients  for  whom  BiVAD
implantation  was  planned.  RVF  was  deﬁned  as  the  unplanned
insertion  of  a  right  VAD  (RVAD)  or  the  use  of  an  intravenous
inotrope  for  14  days  after  surgery  [2—8,10,11].
Statistical analysis
Preoperative  variables  were  compared  between  the  three
groups  with  GraphPad  Prism  5  (GraphPad  Software,  La  Jolla,
CA,  USA).  Continuous  variables  were  compared  in  unpaired
t  tests  for  normally  distributed  variables  and  Wilcoxon
rank-sum  tests  for  non-normally  distributed  variables.  Chi2
or  Fisher’s  exact  tests  were  used  for  categorical  varia-
bles.  Analysis  of  variance  was  used  to  compare  continuous
variables  between  groups.  A  P  value  <  0.05  was  considered
signiﬁcant.  Relative  risks  (RRs)  are  presented  with  95%  conﬁ-
dence  intervals  (CIs).
Multivariable  analyses  were  based  on  stepwise  multi-
ple  logistic  regression  analysis  and  were  used  to  assess
predictors  of  RVF.  BiVAD  patients  were  not  included  in  mul-
tivariable  analyses,  because  they  were  generally  in  a  more
critical  state  and  the  deﬁnition  of  postoperative  RVF  failure
is  more  complex  in  this  speciﬁc  context.  The  following  varia-
bles  were  identiﬁed  as  signiﬁcant  predictors  (P  <  0.05)  in
univariate  analyses  between  the  two  LVAD  groups  and  were,
therefore,  included  in  multivariable  analyses:  INTERMACS
proﬁle,  basal  RVEDD,  minimal  inferior  vena  cava  diameter
and  Em/SLAT ratio.
Bootstrap  estimation  with  resampling  from  1000  simu-
lations  (570  simulations  for  the  RVF  LVAD  group  and  430
simulations  for  the  LVAD  group  without  RVF)  was  used.
Univariate  and  multivariable  analysis  were  performed  on
bootstrap  samples.
An  ARVADE  (assessment  of  right  ventricular  dysfunction
predictors  before  the  implantation  of  a  left  ventricular  assist
device  in  end-stage  heart  failure  patients  using  echocar-
diographic  measures)  score  was  devised  by  rounding  the
exponentiated  regression  model  coefﬁcients  of  independent
predictors  of  RVF  to  the  nearest  0.5.  A  receiver  operat-
ing  characteristic  curve  was  plotted  for  ARVADE  score,  and
the  area  under  the  curve  (AUC)  was  calculated.  AUCs  were
also  calculated  for  Michigan  score  and  for  the  independent
predictors  of  RVF.
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esults
opulation characteristics
uring  the  study  period,  67  patients  received  mechanical
irculatory  support.  We  excluded  18  patients  because  they
ad  received  a  total  artiﬁcial  heart  (11  patients)  or  because
omplete  echocardiographic  evaluations  with  strain  rate
maging  were  not  available  (7  patients;  all  undergoing  emer-
ency  implantation);  thus,  49  patients  were  included  in  the
tudy.  Twenty-seven  patients  received  the  HeartWare  HVAD
HeartWare),  15  patients  received  the  HeartMate  II  (Thor-
tec)  and  seven  patients  received  a  Thoratec  Paracorporeal
iVAD.  Detailed  results  are  shown  in  Table  1.
haracteristics of the population, according to
he presence or absence of a BiVAD
he  patients  in  the  BiVAD  group  were  more  severely  ill
t  the  time  of  mechanical  circulatory  support  implanta-
ion  than  those  of  the  LVAD  groups  (Table  1).  All  BiVAD
atients  had  an  INTERMACS  level  1  proﬁle  and  a  signiﬁ-
antly  higher  Michigan  score  than  the  other  patients.  BiVAD
atients  had  a  signiﬁcantly  lower  RV  stroke  work  index  and
 decreased  pulmonary  capillary  wedge  pressure.  Finally,
oncerning  echocardiographic  variables  (Table  2),  diastolic
ndices  (Em,  ELAT,  Em/ESEPT,  Em/SLAT ratio  and  Em/SSEPT ratio)
ere  increased  in  the  BiVAD  population.
ost-implantation RVF in LVAD patients
wenty-four  LVAD  patients  (57%)  developed  RVF,  11  of  whom
equired  a  temporary  RVAD.
utcome
nhospital  mortality  rates  were  4  of  7  (57%)  in  the  BiVAD
roup,  8  of  24  (33%)  in  the  LVAD  with  RVF  group  and  0  of  18
n  the  LVAD  without  RVF  group  (P  <  0.01).  The  risk  factors  for
eath  in  hospital  identiﬁed  in  the  univariate  analysis  were
VF  (RR  1.95,  95%  CI  1.42—2.66;  P  = 0.002)  and  an  INTERMACS
evel  1  proﬁle  (RR  1.96,  95%  CI  1.09—3.52;  P  =  0.049).
isk factors for RVF in LVAD patients
linical  risk  factors  for  RVF  were  INTERMACS  level  and  pre-
perative  mechanical  ventilation  (Table  1).  Biological  and
aemodynamic  characteristics  and  Michigan  score  were  sim-
lar  in  patients  with  and  without  RVF.
The  associations  between  preoperative  echocardiogra-
hic  characteristics  and  RVF  are  reported  in  Table  2.
ariables  assessing  RV  systolic  function  (SRV, longitudinal
train  and  TAPSE)  tended  to  be  decreased  in  RVF  patients.
nivariate  analysis  identiﬁed  the  following  echocardiogra-
hic  measurements  as  risk  factors  for  RVF:  basal  RVEDD,
inimal  inferior  vena  cava  diameter,  Em,  Em/SLAT ratio  and
m/SSEPT ratio.ndependent predictors of postoperative RVF
ultivariable  analysis  identiﬁed  INTERMACS  level  1,  the
m/SLAT ratio  and  the  basal  RVEDD  as  independent  predictors
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Table  1  Preoperative  patient  characteristics  according  to  postoperative  occurrence  of  RVF.
Characteristic  Study
patients,
(n  =  49)
LVAD
patients
without
RVF,  (n  =  18)
LVAD
patients
with  RVF,
(n  =  24)
BiVAD
patients,
(n  = 7)
Age  (years) 56  [46—67]  60  [48—69]  52  [43—61]  51  [48—57]
Men  44  (90) 18 (100)  21  (88)  5  (71)
BMI  (kg/m2) 25.3  [22.4—27.2] 24.2  [22.7—26.9] 26.0  [22.3—37.0] 26.4  [21.6—28.7]
Ischaemic  aetiology 23  (47) 10 (56) 9 (38) 2 (29)
History  of  COPD  5  (10)  3  (17)  2  (8)  0
Chronic  renal  insufﬁciency  24  (49)  11  (61)  9  (38)  2  (29)
Previous  cardiac  surgery  18  (37)  7  (39)  11  (46)  0
Resynchronization  therapy  20  (41)  10  (56)  6  (25)  4  (57)
Bridge  to  transplantation  33  (67)  11  (61)  15  (63)  7  (100)
Preoperative  mechanical
ventilation
12  (25)  1  (6)  9  (38)a 2  (29)
Preoperative  haemodialysis  9  (18)  3  (17)  3  (13)  3  (43)
Preoperative  IABP  21  (43)  5  (28)b 11  (46)  6  (86)
Preoperative  ECMO  4  (8)  1  (6)  3  (13)  0
Preoperative  inotrope  47  (96)  16  (89)  24  (100)  7  (100)
SOFA  score  4  [3—7]  3  [2—7]  4  [3—5]  7  [7—10]
SAPS  II  30  [23—40]  24  [20—37]b 29  [23—38]  35  [33—42]
Michigan  score  3.0  [0—5.5]  2.3  [0.0—4.1]b 2.8  [0.5—4.4]c 8.5  [7.5—9.5]
INTERMACS  level  1  [1—3]  3  [1—3]b 1  [1—2]a 1  [1]
Serum  sodium  concentration
(mmol/L)
134  [129—136]  135  [128—139]b 135  [131—137]c 126  [125—132]
Blood  urea  nitrogen
concentration  (mg/dL)
76  [54—107]  80.0  [57.5—111.5]  76.0  [54.8—102.8]  111  [63.8—195.5]
Creatinine  concentration
(mg/dL)
1.5 [1.2—2.2]  1.8  [1.3—2.3]  1.3  [1.0—1.8]  2.3  [2.2—3.7]
CRP  concentration  (mg/L)  2.3  [1.0—7.8]  1.7  [0.3—6.2]  2.2  [1.1—6.9]  5.1  [4.4—7.2]
AST  concentration  (IU/L)  31  [25—62]  27  [22—42]  37  [31—49]  31.0  [21.3—185.5]
Bilirubin  concentration  (mg/dL)  1.7  [1.0—2.5]  1.4  [0.6—2.1]b 1.6  [0.9—3.5]c 3.6  [2.6—4.5]
INR  1.5  [1.2—2.3]  2.0  [1.3—2.5]  1.4  [1.1—2.3]  1.5  [1.3—2.0]
Haemoglobin  concentration
(g/dL)
11.9  [10.6—13.5]  12.6  [10.6—13.2]  11.6  [10.4—14.1]  11.8  [10.3—13.5]
Platelets  (109/L)  194  [160—256]  183  [166—233]  232  [166—284]  156  [95—224]
Lactate  concentration  (mmol/L)  1.6  [1.3—2.5]  1.3  [1.0—1.7]b 2.1  [1.6—3.1]  2.7  [1.4—3.0]
Heart  rate  (beats/min)  84  [70—102]  76  [64—83]b 85  [69—105]c 102  [98—120]
Mean  systemic  arterial  pressure
(mmHg)
70  [64—78]  65  [61—75]  65  [58—75]  72  [69—78]
Central  venous  pressure  (mmHg)  16  [12—21]  19  [11—21]  15  [12—22]  16  [15—19]
sPAP  (mmHg)  50  [42—62]  50  [47—58]  51  [36—64]  34  [33—54]
mPAP  (mmHg)  35  [26—44]  35  [28—38]  38  [27—46]  27  [26—42]
PCWP  (mmHg)  28  [19—30]  28  [27—31]b 29  [16—38]c 23  [19—27]
Cardiac  index  (L/min/m2)  1.7  [1.4—1.9]  1.7  [1.4—2.0]  1.8  [1.5—2.3]c 1.4  [1.1—1.6]
PVR  (Dynes/s/cm5/m2)  183  [117—311]  127  [101—223]  193  [134—255]  131  [86—257]
RV  stroke  work  index
(mmHg/m2/L)
2.9 [2.0—4.2]  8.7  [6.7—12.5]b 5.6  [4.3—7.4]c 2.7  [2.1—3.5]
Data are median [interquartile range] or number (%). AST: aspartate aminotransferase; BiVAD: biventricular assist device; BMI: body
mass index; COPD: chronic obstructive pulmonary disorder; CRP: C-reactive protein; ECMO: extracorporeal membrane oxygenation;
IABP: intra-aortic balloon pump; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; INR: international
normalized ratio; LVAD: left ventricular assist device; mPAP: mean pulmonary artery pressure; PCWP: pulmonary capillary wedge
pressure; PVR: pulmonary vascular resistance; RV: right ventricular; RVF: RV failure; SAPS: Simpliﬁed Acute Physiology Score; SOFA:
Sequential Organ Failure Assessment; sPAP: systolic pulmonary artery pressure.
a P < 0.05 for comparison between LVAD patients with and without RVF.
b P < 0.05 for comparison between BiVAD patients and LVAD patients without RVF.
c P < 0.05 for comparison between BiVAD patients and LVAD patients with RVF.
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Table  2  Preoperative  echocardiographic  data,  according  to  the  postoperative  occurrence  of  RVF.
Variables  Patients  without  RVF,  (n  =  18)  RVF  patients,  (n  =  24)  BiVAD  patients,  (n  =  7)
Right  heart
Parasternal  RVEDD  (mm)  39  [35—44]  40  [34—45]  45  [38—42]
Basal  RVEDD  (mm)  42  [38—49]  51  [42—56]a 45  [43—51]
FAC  (%)  21  [16—30]  28  [21—36]  23  [20—33]
SRV (cm/s)  12.6  [9.5—14.2]b 10.0  [7.8—11.9]  9.0  [7.9—11.5]
RV  longitudinal  strain  (%) 9.4  [8.6—11.5] 8.9  [6.9—10.  3]  6.8  [6.4—7.3]
TAPSE  (mm) 17  [13—22] 16  [12—20] 14  [12—18]
ERV (cm/s) 11.6  [9.3—15.3]b 12.6  [9.0—15.0]c 16.7  [14.9—19.3]
RA  area  (cm2) 24 [20—32] 25  [19—35] 35  [27—38]
Maximal  IVC  diameter  (mm) 22  [19—26]b 24  [20—30]c 28  [27—33]
Minimal  IVC  diameter  (mm) 15  [16—26]b 20  [16—29]a,c 28  [20—29]
Et  (cm/s)  49  [35—67]  49  [34—64]  62  [46—78]
Severe  TR  1  (6)  6  (25)  2  (29)
sPAP  (mmHg)  56  [46—63]  54  [38—67]  46  [44—52]
Et/ERV 4.7  [3.8—5.6]  4.6  [3.3—5.3]  3.9  [3.1—4.9]
RVEDD-to-LVEDD  ratio 0.54  [0.47—0.63]  0.48  [0.44—0.64]  0.58  [0.47—0.63]
Left  heart
LVEDD  (mm) 72  [70—76]  77  [67—84]  68  [67—78]
LVEDV  (mL) 250  [184—308] 300  [222—415]  254  [193—355]
LVESV  (mL) 204  [180—300] 233[189—314] 212  [197—259]
LVEF  (%) 17.2  [12.3—23.8] 18.4  [10.6—25.1]  20.7  [15.9—22.6]
SSEPT (cm/s) 4.1  [3.6—6.5] 4.1  [3.2—4.7] 3.5  [3.0—5.5]
SLAT (cm/s) 5.3  [4.7—6.8] 4.5  [3.8—5.4]  5.6  [4.8—7.0]
ESEPT (cm/s) 6.8  [4.4—9.3] 6.0  [4.4—8.0] 7.0  [4.5—8.0]
ELAT (cm/s) 10.3  [5.2—14.6]b 9.5  [7.6—13.9]c 17.5  [11.5—23.2]
LA  area  (cm2) 33 [30—45] 32  [26—47]  39  [29—41]
Aortic  VTI  (cm) 10  [8—12]  11  [8—14]  9  [5—11]
Cardiac  index  (L/min/m2) 1.9  [1.4—2.1] 1.6  [1.1—2.1]  1.4  [1.3—2.4]
Severe  MR 1  (6) 3  (13) 3  (43)
Mitral  deceleration  time  (ms) 95  [88—135] 135  [125—145] 105  [85—132]
Em  (cm/s) 86  [70—93]b 105  [84—132]a 99  [91—132]
Em/ESEPT 12.5  [9.4—18.8]b 16.9  [13.0—26.1]  18.2  [12.2—22.0]
Em/ELAT 8.2  [5.6—12.6] 10.3  [8.3—12.7] 7.2  [4.0—8.7]
Em/SSEPT 17.5  [12.3—26.2]b 27.1  [20.8—32.0]a 28.7  [20.9—33.3]
Em/SLAT 16.3  [10.5—18.2]b 24.4  [18.2—29.2]a,c 19.1  [13.2—22.2]
Data are median [interquartile range] or number (%). BiVAD: biventricular assist device; ERV: tissue Doppler RV diastolic velocity; ELAT:
tissue Doppler lateral diastolic velocity; Em: pulsed Doppler transmitral E wave; ESEPT: tissue Doppler septal diastolic velocity; Et:
pulsed Doppler tricuspid E wave; FAC: RV fractional area change; IVC: inferior vena cava; LA: left atrial; LV: left ventricular; LVAD:
LV assist device; LVEDD: LV end-diastolic diameter; LVEDV: LV end-diastolic volume; LVEF: LV ejection fraction; LVESV: LV end-systolic
volume; MR: mitral regurgitation; RA: right atrial; RV: right ventricular; RVEDD: RV end-diastolic diameter; RVF: RV failure; RVSWI:
RV stroke work index; SLAT: tissue Doppler lateral systolic velocity; sPAP: systolic pulmonary arterial pressure; SRV: tissue Doppler RV
systolic velocity; SSEPT: tissue Doppler septal systolic velocity; TAPSE: maximal systolic excursion of the tricuspid annulus; TR: tricuspid
regurgitation; VTI: velocity-time integral.
a P < 0.05 for comparison between LVAD patients with and without RVF.
b P < 0.05 for comparison between BiVAD patients and LVAD patients without RVF.
c P < 0.05 for comparison between BiVAD patients and LVAD patients with RVF.
Table  3  Independent  predictors  of  post-implantation  RVF.
Factors  RR  for  RVF  95%  conﬁdence  interval  P  value
Em/SLAT ≥  18.5  2.78  1.38—5.60  0.001
Basal  RVEDD  ≥  50  mm  1.97  1.21—3.20  0.008
INTERMACS  level  1  1.74  1.04—2.91  0.04
Em: pulsed Doppler transmitral E wave; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; RR: relative
risk; RVEDD: right ventricular end-diastolic diameter; RVF, right ventricular failure; SLAT: tissue Doppler lateral systolic velocity.
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Figure 1. Receiver operating characteristic curves for the ARVADE
(assessment of right ventricular dysfunction predictors before the
implantation of a left ventricular assist device in end-stage heart
failure patients using echocardiographic measures) score, the Michi-
gan right ventricular score and independent right ventricular failure
predictors. AUC: area under the curve; Em: pulsed Doppler trans-
mitral E wave; INTERMACS: Interagency Registry for Mechanically
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lssisted Circulatory Support; RVEDD: right ventricular end-diastolic
iameter; SLAT: tissue Doppler lateral systolic velocity.
f  RVF  (Table  3).  These  results  were  conﬁrmed  by  bootstrap-
ing.
RVADE score
n  ARVADE  score  was  calculated  as  the  sum  of  points
ttributed  according  to  the  values  of  three  varia-
les:  3.0  points  for  Em/SLAT ≥  18.5,  2.0  points  for  basal
VEDD  ≥  50  mm  and  1.5  points  for  INTERMACS  level  1.  An
RVADE  score  >  3.0  was  predictive  of  post-implantation  RVF,
ith  a  sensitivity  of  89%  and  a  speciﬁcity  of  74%.
Receiver  operating  characteristic  curves  for  the  ARVADE
core,  the  independent  RVF  predictors  identiﬁed  in  our  study
nd  the  Michigan  score  are  shown  in  Fig.  1.  In  our  popula-
ion,  the  Em/SLAT ratio  was  the  independent  predictor  with
he  best  AUC.  The  ARVADE  score  outperformed  the  indepen-
ent  factors  identiﬁed  in  our  study  and  the  Michigan  score
n  predicting  the  occurrence  of  postoperative  RVF  (Fig.  1).
iscussion
he  ﬁndings  of  this  prospective  study  indicate  that  Em/SLAT
as  the  index  that  most  accurately  predicted  RVF  after  LVADmplantation,  showing  that  LV  echocardiographic  variables
ere  the  best  predictors  of  post-LVAD  RVF.  A  straightforward
core  combining  the  results  of  preoperative  clinical  (INTER-
ACS  level  1)  and  echocardiographic  assessments  (Em/SLAT
atio  and  basal  RVEDD)  may  be  a  useful  predictor  of  RVF.
A
I
i
LN.  Aissaoui  et  al.
VF incidence
VF  developed  after  LVAD  implantation  in  57%  of  our
atients.  This  ﬁgure  is  high  but  consistent  with  published
ndings.
Different  deﬁnitions  of  postoperative  RVF  have  been
sed  in  different  studies.  When  we  reviewed  all  studies
eporting  postoperative  RVF  (Table  4)  [3—5,7—10,16—21],
e  found  at  least  ﬁve  deﬁnitions  of  this  condition:  (A)
nplanned  insertion  of  an  RVAD  or  the  use  of  an  intra-
enous  inotrope  for  14  days  after  surgery;  (B)  unplanned
nsertion  of  an  RVAD  or  the  use  of  an  intravenous  inotrope
or  at  least  14  days  after  surgery  or  discharge  from  hos-
ital  on  inotrope  treatment;  (C)  planned  insertion  of  a
iVAD;  (D)  unplanned  insertion  of  an  RVAD;  and  (E)  presence
f  two  of  the  following  criteria  in  the  ﬁrst  48  hours  after
urgery:  mean  arterial  pressure  ≤  55  mmHg,  central  venous
ressure  ≥  16  mmHg,  mixed  venous  saturation  ≤  55%,  car-
iac  index  <  2  L/min/m2,  inotropic  support  score  >  20  units
r  the  need  for  an  RVAD.  RVF  incidence  was  between  9
nd  49%,  depending  on  the  deﬁnition  used.  The  deﬁnition
f  postoperative  RVF  as  unplanned  insertion  of  an  RVAD
ielded  a  lower  incidence,  whereas  incidences  of  almost  50%
ere  reported  for  the  deﬁnition  of  RVF  as  use  of  an  intra-
enous  inotrope  for  14  days  after  surgery  or  the  unplanned
nsertion  of  an  RVAD.  For  LVAD  patients  developing  RVF,  we
btained  an  incidence  of  RVF  of  57%,  consistent  with  the
hree  largest  studies,  which  reported  RVF  incidences  of  40%
o  50%  [3,8,21]. We  used  the  most  widely  used  deﬁnition
ere  [4,17,20,21].
V function in LVAD recipients
fter  LVAD  implantation,  adequate  RV  function  is  required
or  pulmonary  output  and  sufﬁcient  return  to  the  LV  to  sup-
ly  the  pump.  Nevertheless,  in  cases  of  end-stage  heart
ailure  and/or  cardiogenic  shock,  there  is  some  degree  of
V  dysfunction  before  surgery,  clearly  increasing  the  risk  of
VF  [12,13].
RV  behaviour  after  LVAD  implantation  is  difﬁcult  to
redict.  In  most  patients,  RV  function  improves  because
he  afterload  is  decreased  [9,22].  However,  complex
aemodynamic  modiﬁcations,  caused  by  the  leftward  shift
f  the  interventricular  septum,  may  affect  RV  function  dur-
ng  LVAD  implantation.  RV  dysfunction  may  also  be  favoured
y  postoperative  RV  distension,  caused  by  the  perioperative
se  of  blood  products  and  crystalloids,  and  intraoperative
V  injury  [18].
RVF  in  LVAD  recipients  results  in  higher  mortality  [2].  In
ur  study,  RVF  was  associated  with  inhospital  mortality.  It
s,  therefore,  important  to  identify  those  patients  who  are
ikely  to  develop  RVF.
ssessment of RV functiont  is  difﬁcult  to  predict  the  adequacy  of  RV  function  and
ts  capacity  to  respond  to  variations  in  loading  conditions  in
VAD  patients  before  surgery.
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Table  4  Deﬁnitions  and  incidences  of  postoperative  RVF  in  previous  studies.
Study  Deﬁnition  of  RVF  Patient  numbers  Study  period  Incidence  of  RVFa
Fukamachi  et  al.  [19]  D  100  1991—1996  11  (11)
Kavarana  et  al.  [20]  A  69  1996—1999  21  (30.4)
Ochiai  et  al.  [5]  D  245  1991—2001  23  (9)
Dang  et  al.  [16]  A  108  1996—2004  42  (39)
Potapov  et  al.  [3]  C  970  1987—2006  485  (49)
Matthews  et  al.  [4] A  197  1996—2006  68  (35)
Potapov  et  al.  [10] E  54  1998—2006 8  (17)
Fitzpatrick  et  al.  [18] C  266  1995—2007 99  (37)
Deng  et  al.  [17]  Unclear  542  2002—2004  44  (11)
Patel  et  al.  [21]  A  73  2000—2007  29  (40)
Kormos  et  al.  [7]  B  484  2005—2008  98  (20)
Kukucka  et  al.  [9]  E  115  2007—2009  15  (13)
Grant  et  al.  [8]  A  117  2007—2011  47  (40)
A: unplanned insertion of a right ventricular assist device (RVAD) or the use of an intravenous inotrope for 14 days after surgery;
B: unplanned insertion of an RVAD or the use of an intravenous inotrope for at least 14 days after surgery or hospital discharge on
inotrope treatment; C: planned insertion of a biventricular assist device; D: unplanned insertion of an RVAD; E: presence of two of
the following criteria in the ﬁrst 48 hours after surgery: mean arterial pressure ≤ 55 mmHg, central venous pressure ≥ 16 mmHg, mixed
venous saturation ≤ 55%, cardiac index < L/min/m2, inotropic support score > 20 units or the need for an RVAD; RVF: right ventricular
failure.
a Data are number (%).
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fLimitations of biological measurements
Previous  studies  identiﬁed  congestion  biomarkers,  includ-
ing  urea,  creatinine,  aminotransferase  and  bilirubin
concentrations,  and  prothrombin  time  as  risk  factors  for
RVF  development  [4].  However,  these  markers  are  not  spe-
ciﬁc  for  RVF  and  may  reﬂect  poor  kidney  perfusion  and
liver  congestion  in  the  context  of  severely  decompensated
global  heart  failure.  In  our  population  of  patients  selected
for  LVAD,  neither  biological  markers  nor  the  Michigan  RV
score  was  associated  with  the  post-LVAD  risk  of  RVF.  This
may  be  because  a  high  Michigan  RV  score  is  used  as  a cri-
terion  for  selecting  patients  for  planned  BiVAD  implantation
at  our  institution.  Thus,  in  our  study,  the  Michigan  RV  score
was  higher  in  the  planned  BiVAD  group  than  in  the  other
groups.  Alternatively,  these  results  may  reﬂect  the  timing
of  biological  data  collection.  We  recorded  biological  data  on
the  day  of  implantation,  in  patients  stabilized,  as  required,
with  inotrope  treatment.  The  status  of  almost  all  patients
was  therefore  better  than  that  at  admission.  Previous  stud-
ies  using  the  Michigan  RV  score  to  predict  the  occurrence
of  RVF  after  LVAD  implantation  did  not  report  the  timing  of
biological  data  collection  [4,8].
Invasive haemodynamic measurements
Pulmonary  arterial  blood  pressure,  pulmonary  vascular  resis-
tance,  central  venous  blood  pressure  and  RV  stroke  work
index  have  been  identiﬁed  as  risk  factors  for  RVF  [5,7].
However,  the  results  of  different  studies  diverge  and,  in
our  study,  no  invasive  haemodynamic  measurement  discrimi-
nated  between  LVAD  patients  with  and  without  RVF,  although
the  RV  stroke  work  index  was  lower  in  BiVAD  patients.  The
use  of  invasive  haemodynamic  indices  to  select  patients  for
BiVAD  implantation  might  account  for  our  results.
h
a
a
ahe value of echocardiographic assessments
ransthoracic  echocardiography  is  non-invasive  and
eadily  available  at  the  patient’s  bedside.  However,
chocardiographic  assessment  is  particularly  difﬁcult  for
he  RV,  because  of  its  complex  geometry  [15].
V function variables
ome  indices  assessing  RV  systolic  function  have  been  iden-
iﬁed  as  predictors  of  RVF  after  LVAD  implantation;  they
nclude  TAPSE  <  7.5  mm,  RV  fractional  area  shortening  and
ongitudinal  strain  <  −9.6%  [8—11].  In  our  population,  these
arkers  were  not  discriminating.  There  are  several  possible
easons  for  this:  previous  cardiac  surgery  (a  factor  present
n  43%  of  our  patients)  can  interfere  with  RV  systolic  indices
nd/or  function  [22],  RV  function  measurements  are  load
ependent  and  load  conditions  differed  before  and  after
VAD  implantation.  Uncertainties  concerning  delineation  of
he  RV  endocardium  in  some  patients  may  have  contributed
o  our  negative  results  [15].
Basal  RVEDD  is  associated  with  the  risk  of  developing
VF  after  LVAD  implantation.  Thus  in  our  hands,  the  echo-
ardiographic  measurements  predictive  of  RVF  after  LVAD
mplantation  were  not  those  assessing  RV  systolic  function,
ut  those  reﬂecting  RV  congestion  [9,10].
ulmonary circulatory function variables
hronic  sustained  increases  in  blood  pressure  in  the  pul-
onary  capillaries  caused  by  pulmonary  venous  congestion
nd  pulmonary  venous  hypertension  lead  to  RV  overload  and
ailure.  Variables  assessing  pulmonary  circulatory  function
ave  been  reported  in  previous  studies  aiming  to  predict  RVF
fter  LVAD  implantation  [4,5,13,18—20].  In  a  retrospective
nalysis  assessing  337  patients,  pulmonary  blood  pressure
nd  pulmonary  capillary  wedge  pressure  were  found  to  be
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he  most  important  haemodynamic  determinants  of  RV  func-
ion  in  both  decompensated  and  stable  systolic  heart  failure
13].  In  our  study,  among  echocardiographic  variables,
ystolic  pulmonary  pressure  failed  to  differentiate  between
he  different  groups,  whereas  variables  assessing  the  dia-
tolic  function  of  the  LV  were  identiﬁed  as  risk  factors  for
ostoperative  RVF.
V function variables
ne  study  to  date  has  highlighted  the  potential  value  of
ssessing  LV  function  for  the  evaluation  of  RV  function  and
he  identiﬁcation  of  patients  at  risk  of  RVF  after  LVAD
mplantation  [12].  This  study  reported  that  LV  measurements
LV  diameters,  LV  ejection  fraction  and  left  atrial  diame-
er/LV  end-diastolic  diameter  ratio)  could  help  to  identify
atients  at  risk  of  developing  postoperative  RVF.
In  our  study,  some  variables  assessing  LV  function  were
dentiﬁed  as  risk  factors  for  RVF  after  LVAD  implantation:
m,  Em/SSEPT ratio  and  Em/SLAT ratio.
The  E  wave  is  dependent  on  fast  passive  ﬁlling  and  dia-
tolic  LV  function;  a  high  E  wave  reﬂects  high  capillary  wedge
ressures  and,  indirectly,  a  high  RV  afterload  [23]. A  study
n  16  anaesthetized  dogs  with  closed  chests  showed  that  the
 wave  was  strongly  related  to  LV  contractility  and  after-
oad  (R  =  0.906)  [24].  This  relationship  led  the  authors  to
onclude  that  relaxation  was  closely  related  to  systolic  func-
ion.  We  considered  the  E  wave  to  reﬂect  not  only  high
apillary  wedge  pressures,  but  also  severe  impairments  of
V  contractility.
Similarly,  early  ELATs  assessing  LV  relaxation  were  also
ound  to  differ  between  BiVAD  and  LVAD  patients.
The  normalization  of  the  E  wave  value  by  longitudinal
unction  makes  a  major  contribution  to  the  evaluation  of
V  ﬁlling  pressure:  Em/ELAT and  Em/ESEPT ratios  [23].  Here,
e  have  expanded  this  concept  slightly,  by  calculating  the
m/SLAT and  Em/SSEPT ratios.
The  Em/SLAT ratio  was  the  best  echocardiographic  index
or  identifying  postoperative  RVF.  A  low  SLAT reﬂects  severe
V  systolic  dysfunction.  Moreover,  it  is  a  load-independent
easure  [25].
We  would  expect  that  the  interventricular  septum  sys-
olic  impairment  would  be  more  relevant  than  the  lateral
all  and  the  Em/SSEPT stronger  than  the  Em/SLAT for  predict-
ng  RVF  failure  after  LVAD  implantation.  The  RV  is  linked  to
he  LV  via  the  shared  septal  wall,  the  pericardial  space  and
he  mutually  encircling  epicardial  ﬁbres,  and  because  the
V  free  wall  is  attached  to  the  anterior  and  posterior  sep-
um  [26].  We  ﬁnd,  paradoxically,  that  Em/SLAT,  reﬂecting  LV
unction,  was  the  index  that  most  accurately  predicted  RVF
fter  LVAD  implantation,  showing  the  strong  contribution  of
he  LV  to  RVF.
RV  dysfunction  is  a  consequence  of  LV  dysfunction  in  cases
f  end-stage  heart  failure  ischaemic  cardiomyopathy,  and
hese  two  dysfunctions  progress  together  in  cases  of  dilated
ardiomyopathy.
As  it  is  difﬁcult  to  assess  RV  function,  an  assessment
f  LV  systolic  function  can  be  used  to  evaluate  RV  func-
ion.  LV  echocardiographic  variables  are  not  affected  by
ardiac  surgery  [22].  It  is,  therefore,  not  particularly  sur-
rising  that  a  LV  measurement  was  the  best  predictor  of
VF  after  LVAD  implantation.  Nevertheless,  this  factor  alone
D
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oes  not  provide  a  satisfactory  prediction  of  RVF  after  LVAD
mplantation.
he usefulness of a score for predicting RVF in
VAD patients
he  large  number  of  factors  responsible  for  RVF  after  LVAD
mplantation  justify  the  development  of  scores  for  predict-
ng  the  risk  of  postoperative  RVF  [4,5,18].
Our  score  is  a simple  tool  combining  one  clinical
rognostic  marker—the  INTERMACS  level  [14]—and  three
asily-obtained  echocardiographic  measurements  reﬂecting
V  congestion  and  LV  function.  Our  score  outperformed  the
ichigan  score  in  our  study;  these  two  scores  are  comple-
entary.  Critically  ill  patients  with  a  high  Michigan  score
hould  undergo  BiVAD  implantation.  The  difﬁculty  in  routine
linical  practice  is  identifying  the  ‘less  severely  ill’  patients
ikely  to  develop  postoperative  RVF.  The  ARVADE  score  could
e  useful  for  this.  Prospective  validation  of  this  tool  with  a
arge  population  is  required  before  its  use  can  be  general-
zed.
tudy limitations
he  deﬁnition  of  RVF  remains  problematic  for  the  classiﬁca-
ion  of  patients.  Indeed,  the  deﬁnition  ‘unplanned  insertion
f  an  RVAD  or  the  use  of  an  intravenous  inotrope  for  14
ays  postoperatively’  covers  a  very  large  and  heterogeneous
opulation.
Other  limitations  of  our  study  include  the  small  number
f  patients  and  the  monocentric  character  of  our  cohort.
onclusion
he  occurrence  of  RVF  following  LVAD  implantation  is  a
evere  complication,  associated  with  excess  mortality.
The  echocardiographic  variables  assessing  the  LV  were
he  best  predictors  of  post-LVAD  RVF,  showing  the  strong
ontribution  of  the  LV  to  RVF.
The  ARVADE  score,  calculated  as  the  sum  of  scores  for
ne  clinical  prognostic  marker  (INTERMACS  level)  and  three
asily  obtainable  echocardiographic  measures  (Em/SLAT and
asal  RVEDD)  reﬂecting  LV  global  systolic  and  diastolic  dys-
unction  and  RV  congestion,  may  facilitate  the  identiﬁcation
f  suitable  patients  for  device  implantation.
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